AtriCure Bipolar Ablation System released to market including second-generation Bipolar Ablation Clamp (LHP2) and second-generation Ablation Sensing Unit (ASU2)
AtriCure received its first CE Mark approval that included the Bipolar Ablation System
Washington University published the seminal paper on AtriCure’s Bipolar Radiofrequency Technology
2003
Foundational patent 6,517,536 and 6,546,935 issued for “Device and Methods for Transmural Ablation”
First commercial sale that included the Bipolar Ablation Clamp
2004
Lumitip™ Dissector released to market
First international sale that was sold to Belgium
2005
Isolator® Transpolar™ Pen (MAX1) released to market
AtriCure listed on NASDAQ
AtriCure opened its European office in the Netherlands
2006
Isolator® Transpolar™ Long Pen (MAX5) released to market
Isolator® Transpolar™ System released to market including the Isolator Clamps (OLL1, EMR1 and EML1)
2007
AtriCure Synergy Bipolar Ablation System released to market including the Isolator Synergy Clamps (OLL2, OSL2, EMR2 and EML2) along with AtriCure Switch Matrix (ABS3)
First AtriClip device implanted
AtriCure entered the Cryosurgical market
2008
Isolator Coolrail® Linear Pen released to market
ABLATE Clinical Trial enrollment initiated
EXCLUDE Clinical Trial enrollment initiated
Continued to grow international presence by selling products in over 25 countries
2009
CRYO1 Cryoablation Probe released to market
ORLab® System released to market
DEEP (Hybrid) Clinical Trial enrollment initiated
2010
AtriClip Left Atrial Appendage (LAA) Exclusion System released to market
AtriClip ACH1 device released to market
CRYO2 cryoICE® Cryoablation Probe released to market
Multifunctional Linear Pen released to market
2011
AtriCure Cryo Module System released to market
Isolator Synergy System approved for treatment of persistent or long-standing persistent atrial fibrillation
Isolator Synergy Access Clamp released to market
2012
AtriClip PRO® device released to market
DEEP (Staged) Clinical Trial enrollment initiated
Maze IV Training Program initiated
AtriCure hosted 25th Anniversary of the Cox Maze Procedure
Over 100,000 ablations performed
2013
Established Professional Education Program
AtriCure expanded the Maze IV Training Program to Europe
AtriCure acquired Endoscopic Technologies, Inc. (Estech)
2014
AtriClip FLEX device (ACH2) released to market
CRYO3 cryoICE Cryoablation Probe and AtriCure Cryo Module Version 6 (ACM V6) released to market
ABLATE-PAS Clinical Trial completes enrollment
DEEP (Pivotal) Clinical Trial enrollment initiated
Completed requirement to train U.S. surgeons on Synergy Clamp per FDA mandate
Minneapolis office opened
Over 150,000 ablations performed
2015
cryoICE® probe made available for Cryo Nerve Block applications
CEASE-AF Clinical Trial enrollment initiated
Dr. James L. Cox American Association for Thoracic Surgery (AATS) Fellowship Training Program established
Introduced Advanced Ablation weekend training courses
Facility expansions at headquarters and European location
The Society of Thoracic Surgeons (STS) endorses AtriCure’s Advanced Ablation Courses in the United States
Over 2,500 healthcare professionals trained, more than 350,000 ablations performed, and surpassed 200,000 AtriClip devices sold worldwide
2020
MO100000 marked the 100,000th production build
aMAZE Clinical Trial completes enrollment
Cincinnati headquarters earned “Top Workplaces 2020” designation along with its Minnetonka office being named a “2020 National Standard Top Workplace” by the Minneapolis Star Tribune
2021
Received expanded labeling for Cryo Nerve Block Therapy
EPi-Sense® Guided Coagulation System approved for treatment of long-standing persistent atrial fibrillation